Cilta-cel Provides Durable Responses in Lenalidomide-Refractory Myeloma After 1 to 3 Prior Lines

August 28, 2022Kristi RosaCiltacabtagene autoleucel elicited encouraging responses in patients with multiple myeloma who had received 1 to 3 prior lines of therapy and were refractory to lenalidomide.

Updated on: October 17,2023

Cilta-cel Provides Durable Responses in Lenalidomide-Refractory Myeloma After 1 to 3 Prior Lines

August 28, 2022Kristi RosaCiltacabtagene autoleucel elicited encouraging responses in patients with multiple myeloma who had received 1 to 3 prior lines of therapy and were refractory to lenalidomide.

Updated on:October 17,2023

ICI-Treated Synchronous mRCC Is Associated With Negative Survival Outcomes

July 17, 2023Ashling WahnerPatients with synchronous metastatic renal cell carcinoma who received first-line immunotherapy had worse survival outcomes compared with those with metachronous metastatic

Updated on: October 15,2023

ICI-Treated Synchronous mRCC Is Associated With Negative Survival Outcomes

July 17, 2023Ashling WahnerPatients with synchronous metastatic renal cell carcinoma who received first-line immunotherapy had worse survival outcomes compared with those with metachronous metastatic

Updated on:October 15,2023

Mayo Clinic researchers study immunity-boosting vaccine to target aggressive form of breast cancer

by From Mayo Clinic News Network, Mayo Clinic News NetworkThree-dimensional culture of human breast cancer cells, with DNA stained blue and a protein in the cell surface membrane stained green. Image

Updated on: December 18,2023

Mayo Clinic researchers study immunity-boosting vaccine to target aggressive form of breast cancer

by From Mayo Clinic News Network, Mayo Clinic News NetworkThree-dimensional culture of human breast cancer cells, with DNA stained blue and a protein in the cell surface membrane stained green. Image

Updated on:December 18,2023

Large study links sustained weight loss to reduced breast cancer risk

byAmerican Cancer SocietyCredit: CC0 Public DomainA large new study finds that women who lost weight after age 50 and kept it off had a lower risk of breast cancer than women whose weight remain

Updated on: December 22,2023

Large study links sustained weight loss to reduced breast cancer risk

byAmerican Cancer SocietyCredit: CC0 Public DomainA large new study finds that women who lost weight after age 50 and kept it off had a lower risk of breast cancer than women whose weight remain

Updated on:December 22,2023

Addition of maintenance olaparib slows advanced ovarian cancer

(HealthDay)—Compared with placebo, the addition of olaparib to maintenance therapy with bevacizumab is associated with a significant progression-free survival benefit for patients with advanced ovaria

Updated on: December 22,2023

Addition of maintenance olaparib slows advanced ovarian cancer

(HealthDay)—Compared with placebo, the addition of olaparib to maintenance therapy with bevacizumab is associated with a significant progression-free survival benefit for patients with advanced ovaria

Updated on:December 22,2023

AI's Breakthroughs in Ovarian Cancer Diagnosis and Treatment

Updated on: June 12,2024

AI's Breakthroughs in Ovarian Cancer Diagnosis and Treatment

Updated on:June 12,2024

Study finds less-aggressive chemotherapy after initial treatment for metastatic colorectal cancer to be more beneficial

byMayo ClinicCancer—Histopathologic image of colonic carcinoid. Credit: Wikipedia/CC BY-SA 3.0A Mayo Clinic study involving 5,540 patients with metastatic colorectal cancer finds that maintenanc

Updated on: December 22,2023

Study finds less-aggressive chemotherapy after initial treatment for metastatic colorectal cancer to be more beneficial

byMayo ClinicCancer—Histopathologic image of colonic carcinoid. Credit: Wikipedia/CC BY-SA 3.0A Mayo Clinic study involving 5,540 patients with metastatic colorectal cancer finds that maintenanc

Updated on:December 22,2023

Fred Hutch experts highlight research on cancer treatment advances, survivorship and precision oncology at ASCO

At the 2023 American Society for Clinical Oncology Annual Meeting—to be held June 2-6 in Chicago, Illinois—Fred Hutchinson Cancer Center experts will present research spanning survivorship, advances i

Updated on: November 21,2023

Fred Hutch experts highlight research on cancer treatment advances, survivorship and precision oncology at ASCO

At the 2023 American Society for Clinical Oncology Annual Meeting—to be held June 2-6 in Chicago, Illinois—Fred Hutchinson Cancer Center experts will present research spanning survivorship, advances i

Updated on:November 21,2023

Study points to new possibilities for treating lung cancer patients

by Birgitte Svennevig,University of Southern DenmarkAn EMT-centric investigation of metabolic processes in a comprehensive lung cancer transcriptome profiles collection identified an inverse ass

Updated on: May 25,2024

Study points to new possibilities for treating lung cancer patients

by Birgitte Svennevig,University of Southern DenmarkAn EMT-centric investigation of metabolic processes in a comprehensive lung cancer transcriptome profiles collection identified an inverse ass

Updated on:May 25,2024

Multicenter Review Supports TKI Use in Patients With mRCC and Bone Metastases

September 20, 2022Megan HollaschAn analysis of patterns of care and outcomes for patients with metastatic renal cell carcinoma with bone metastases supported the role of TKIs as the standard of care.&

Updated on: October 17,2023

Multicenter Review Supports TKI Use in Patients With mRCC and Bone Metastases

September 20, 2022Megan HollaschAn analysis of patterns of care and outcomes for patients with metastatic renal cell carcinoma with bone metastases supported the role of TKIs as the standard of care.&

Updated on:October 17,2023

Pembrolizumab Active in Advanced Nasopharyngeal Carcinoma

August 29, 2017Jason HarrisPembrolizumab (Keytruda) induced an overall response rate of 25.9% and was well tolerated in patients with PD-L1–positive recurrent or metastatic nasopharyngeal carcinoma.Na

Updated on: October 24,2023

Pembrolizumab Active in Advanced Nasopharyngeal Carcinoma

August 29, 2017Jason HarrisPembrolizumab (Keytruda) induced an overall response rate of 25.9% and was well tolerated in patients with PD-L1–positive recurrent or metastatic nasopharyngeal carcinoma.Na

Updated on:October 24,2023

Study uncovers the role of NETO2-mediated regulation in melanoma progression

by Frontiers JournalsCredit:Frontiers of Medicine(2023). DOI: 10.1007/s11684-022-0935-0Cong Peng and others at the Department of Dermatology, Xiangya Hospital, Central South University, Ch

Updated on: August 27,2024

Study uncovers the role of NETO2-mediated regulation in melanoma progression

by Frontiers JournalsCredit:Frontiers of Medicine(2023). DOI: 10.1007/s11684-022-0935-0Cong Peng and others at the Department of Dermatology, Xiangya Hospital, Central South University, Ch

Updated on:August 27,2024